Quick Answer
iBio, Inc. reported Diluted EPS of $1.75 per share (loss) for fiscal year 2025.
iBio, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.75 | +73.1% |
| 2024 | -$6.50 | +93.9% |
| 2023 | -$106.19 | -1737.2% |
| 2022 | -$5.78 | -92.7% |
| 2021 | -$3.00 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | -$0.09 | +81.3% | +18.2% |
| September 30, 2025 | -$0.11 | +76.1% | +77.6% |
| March 31, 2025 | -$0.49 | +42.4% | -2.1% |
| December 31, 2024 | -$0.48 | +89.1% | -4.3% |
| September 30, 2024 | -$0.46 | +90.4% | +45.9% |
| March 31, 2024 | -$0.85 | +92.3% | +80.8% |
| December 31, 2023 | -$4.42 | +93.5% | +7.9% |
| September 30, 2023 | -$4.80 | -134.1% | +56.6% |
- iBio, Inc. showed an increase of +73.1% in Diluted EPS compared to the prior fiscal year.
- Over the 2021–2025 period, iBio, Inc.’s diluted eps has grown by 41.7% (from $3.00 per share (loss) to $1.75 per share (loss)).
- The most recent figure is from iBio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 5, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: